by International Federation of Psoriasis Associations with support from Lucid
by Sanofi Diabetes
by Astellas Pharma Ltd with support from Wizzard
by Boehringer Ingelheim with support from infill Kommunikation GmbH
by Crohn’s and Colitis UK with support from Healthcare Solutions PR
by GSK with support from emotive
by Janssen with support from Havas Lynx
by Astellas Pharma Ltd with support from Wizzard
In 2009 Astellas embarked on a project working in partnership with the Bladder and Bowel Foundation to engage with patients suffering from the condition overactive bladder (OAB) who were not fully aware that their symptoms related to a treatable medical condition.
This disease awareness programme is unique in two key respects:
Now entering its fifth year the programme has supported over half a million patients with OAB to seek help and advice and for many to gain control over their symptoms and improve their quality of life.
Yet another very credible entry from Astellas and once again we are impressed by their very clear customer focus and what they have achieved with this ongoing campaign.
Entry deadline | 26 August 2022 |
Extended entry deadline | 2 September 2022* *additional fee applies |
Judging Day | 6 October 2022 |
Company/Team of the Year Interviews | 21 October 2022 |
PMEA Event | 23 November 2022 |